Veradigm Amends and Extends Stockholder Rights Plan
Veradigm (OTCMKTS: MDRX) announced that its Board of Directors has approved an amendment to extend its existing Stockholder Rights Plan from February 26, 2025, to August 20, 2025. The amendment updates the exercise price for rights purchase from $50.00 to $32.00.
The extension is driven by ongoing challenges including: the continuing audit of 2022 financial statements, delayed financial reporting due to restatement requirements, and the company's delisted status. The Board noted these factors make tracking share accumulation particularly challenging. The decision was also influenced by a significant stock price decline following the termination of strategic alternatives exploration.
The Rights Plan aims to protect stockholders from potential rapid share accumulations or creeping acquisitions of control without payment of appropriate control premiums. The plan doesn't prevent the company from considering fair offers that benefit stockholders.
Veradigm (OTCMKTS: MDRX) ha annunciato che il suo Consiglio di Amministrazione ha approvato una modifica per estendere il suo attuale Piano dei Diritti degli Azionisti dal 26 febbraio 2025 al 20 agosto 2025. La modifica aggiorna il prezzo di esercizio per l'acquisto dei diritti da $50,00 a $32,00.
L'estensione è motivata da sfide in corso, tra cui: l'audit continuo dei bilanci finanziari del 2022, il ritardo nella reportistica finanziaria a causa dei requisiti di rettifica e lo stato di delisting della società. Il Consiglio ha notato che questi fattori rendono particolarmente difficile il monitoraggio dell'accumulo di azioni. La decisione è stata inoltre influenzata da un significativo calo del prezzo delle azioni dopo la cessazione dell'esplorazione di alternative strategiche.
Il Piano dei Diritti mira a proteggere gli azionisti da potenziali accumuli rapidi di azioni o acquisizioni di controllo graduali senza il pagamento di premi adeguati per il controllo. Il piano non impedisce alla società di considerare offerte eque che possano avvantaggiare gli azionisti.
Veradigm (OTCMKTS: MDRX) anunció que su Junta Directiva ha aprobado una enmienda para extender su actual Plan de Derechos de Accionistas desde el 26 de febrero de 2025 hasta el 20 de agosto de 2025. La enmienda actualiza el precio de ejercicio para la compra de derechos de $50.00 a $32.00.
La extensión está motivada por desafíos continuos, incluyendo: la auditoría de los estados financieros de 2022, el retraso en la presentación de informes financieros debido a requisitos de rectificación y el estado de deslistado de la empresa. La Junta señaló que estos factores hacen que el seguimiento de la acumulación de acciones sea particularmente desafiante. La decisión también fue influenciada por una caída significativa en el precio de las acciones tras la finalización de la exploración de alternativas estratégicas.
El Plan de Derechos tiene como objetivo proteger a los accionistas de posibles acumulaciones rápidas de acciones o adquisiciones de control graduales sin el pago de primas de control adecuadas. El plan no impide que la empresa considere ofertas justas que beneficien a los accionistas.
Veradigm (OTCMKTS: MDRX)는 이사회의 승인을 받아 현재의 주주 권리 계획을 2025년 2월 26일에서 2025년 8월 20일로 연장한다고 발표했습니다. 이 수정안은 권리 구매를 위한 행사 가격을 $50.00에서 $32.00로 업데이트합니다.
이번 연장은 2022년 재무제표에 대한 지속적인 감사, 수정 요구로 인한 재무 보고 지연, 회사의 상장 폐지 상태 등 여러 지속적인 도전 과제로 인해 이루어졌습니다. 이사회는 이러한 요소들이 주식 축적을 추적하는 데 특히 어렵게 만든다고 언급했습니다. 또한, 전략적 대안 탐색 종료 이후 주가의 급격한 하락이 결정에 영향을 미쳤습니다.
권리 계획은 주주들이 적절한 통제 프리미엄 없이 빠른 주식 축적이나 점진적인 통제 인수로부터 보호하는 것을 목표로 합니다. 이 계획은 회사가 주주에게 이익이 되는 공정한 제안을 고려하는 것을 방해하지 않습니다.
Veradigm (OTCMKTS: MDRX) a annoncé que son Conseil d'Administration a approuvé un amendement pour prolonger son Plan de Droits des Actionnaires existant du 26 février 2025 au 20 août 2025. L'amendement met à jour le prix d'exercice pour l'achat des droits de 50,00 $ à 32,00 $.
Cette extension est motivée par des défis persistants, notamment : l'audit continu des états financiers de 2022, le retard dans le reporting financier en raison des exigences de redressement et le statut de radiation de l'entreprise. Le Conseil a noté que ces facteurs rendent particulièrement difficile le suivi de l'accumulation d'actions. La décision a également été influencée par une baisse significative du prix des actions suite à la cessation de l'exploration d'alternatives stratégiques.
Le Plan de Droits vise à protéger les actionnaires contre d'éventuelles accumulations rapides d'actions ou des acquisitions de contrôle progressives sans paiement de primes de contrôle appropriées. Le plan n'empêche pas l'entreprise d'envisager des offres équitables qui bénéficient aux actionnaires.
Veradigm (OTCMKTS: MDRX) gab bekannt, dass der Vorstand eine Änderung genehmigt hat, um den bestehenden Aktionärsrechteplan vom 26. Februar 2025 bis zum 20. August 2025 zu verlängern. Die Änderung aktualisiert den Ausübungspreis für den Erwerb von Rechten von 50,00 $ auf 32,00 $.
Die Verlängerung wird durch anhaltende Herausforderungen wie die fortlaufende Prüfung der Finanzberichte für 2022, verzögerte Finanzberichterstattung aufgrund von Anpassungsanforderungen und den Status der Delistung des Unternehmens vorangetrieben. Der Vorstand stellte fest, dass diese Faktoren die Nachverfolgung der Aktienakkumulation besonders schwierig machen. Die Entscheidung wurde auch durch einen signifikanten Rückgang des Aktienkurses nach der Beendigung der Erkundung strategischer Alternativen beeinflusst.
Der Rechteplan zielt darauf ab, die Aktionäre vor möglichen schnellen Aktienakkumulationen oder schleichenden Kontrollübernahmen ohne Zahlung angemessener Kontrollprämien zu schützen. Der Plan hindert das Unternehmen jedoch nicht daran, faire Angebote zu prüfen, die den Aktionären zugutekommen.
- None.
- Company remains delisted from major exchanges
- 2022 financial statements still under audit
- Financial reporting will remain non-current for an extended period
- Significant stock price decline following termination of strategic alternatives
- Required restatement of financial statements
The Rights Plan, adopted on February 26, 2024, was due to expire on February 26, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to August 20, 2025. To reflect changes in the price of Company common stock since February 26, 2024, the amendment to the Rights Plan also updates the exercise price for the purchase of rights under the Rights Plan from
The Board's decision to extend the Rights Plan is based on its determination that many of the underlying risks and conditions that existed upon the initial adoption of the Rights Plan continue to be present, including (i) the ongoing audit of the Company’s 2022 financial statements, (ii) the fact that as a result of the 2022 audit and related restatement, the Company will not be current in its financial reporting for some time and (iii) the fact that Company common stock remains delisted and tracking an accumulation of shares is particularly challenging for unlisted shares. In addition, there has been a significant decline in the price of Company common stock since the Company announced the termination of the exploration of strategic alternatives.
As a result, the Board believes Veradigm and its stockholders remain vulnerable to rapid and significant accumulation of stock and derivative positions, as well as potential creeping acquisitions of actual or “de facto” control, whereby an investor could acquire a substantial percentage of outstanding shares of Company common stock prior to making any public disclosure regarding its control intent and without paying a control premium.
The Rights Plan was implemented to ensure that all Veradigm stockholders have the opportunity to realize the full potential value of their investment. By extending this protective measure, the Board seeks to safeguard stockholder interests by reducing the likelihood of any person’s or group’s obtaining control through open market accumulation or otherwise without appropriately compensating all stockholders. The Rights Plan does not prevent the Company from pursuing any offer that is fair and otherwise in the best interests of stockholders.
Further details about the Rights Plan, as amended, will be contained in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
Sidley Austin LLP is serving as legal counsel and J.P. Morgan Securities LLC is serving as financial advisor to the Company.
About Veradigm®
Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.
© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or Company names are the property of their respective holders, all rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220994975/en/
Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com
Media:
Concetta Rasiarmos
630-740-3152
concetta.rasiarmos@veradigm.com
Source: Veradigm
FAQ
When will Veradigm's (MDRX) extended Stockholder Rights Plan expire?
What is the new exercise price for rights under Veradigm's (MDRX) amended Rights Plan?
Why did Veradigm (MDRX) extend its Stockholder Rights Plan?
What are the main challenges facing Veradigm (MDRX) according to the Rights Plan extension?
